Pulse pressure monitoring of open antihypertensive therapy.

[1]  A. Evans,et al.  Residual coronary risk in men aged 50–59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study , 2004, Journal of hypertension.

[2]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[3]  Y. Lacourciére,et al.  Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements , 2003, Journal of hypertension.

[4]  H. Struijker‐Boudier,et al.  Current Perspectives on Arterial Stiffness and Pulse Pressure in Hypertension and Cardiovascular Diseases , 2003, Circulation.

[5]  Claude Lenfant,et al.  Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. , 2003, Hypertension.

[6]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[7]  Bryan Williams,et al.  Treating hypertension: it is not how you start but where you end that matters. , 2003, Journal of hypertension.

[8]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[9]  Martin G Myers,et al.  Gender influence on the dose-ranging of a low-dose perindopril–indapamide combination in hypertension: effect on systolic and pulse pressure , 2002, Journal of hypertension.

[10]  M. Pfeffer,et al.  Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). , 2002, JAMA.

[11]  C. Bulpitt,et al.  Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. , 2002, American journal of hypertension.

[12]  M E Safar,et al.  Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections With a Very-Low-Dose Perindopril/Indapamide Combination in Hypertensive Patient: A Comparison With Atenolol , 2001, Hypertension.

[13]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[14]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[15]  M. Safar,et al.  Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. , 2001, American journal of hypertension.

[16]  R. Asmar,et al.  Reference values for clinic pulse pressure in a nonselected population. , 2001, American journal of hypertension.

[17]  R. Asmar,et al.  A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. , 2000, Journal of hypertension.

[18]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[19]  V. Burke,et al.  Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. , 1999, Journal of hypertension.

[20]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[21]  P. Palatini,et al.  Ambulatory blood pressure predicts end-organ damage only in subjects with reproducible recordings , 1999 .

[22]  Anne Harrington,et al.  The Placebo Effect: An Interdisciplinary Exploration , 1999 .

[23]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.